G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?
Black or African American
COVID-19
/ blood
COVID-19 Nucleic Acid Testing
Contraindications, Drug
Critical Care
Female
Genetic Predisposition to Disease
Glucosephosphate Dehydrogenase Deficiency
/ blood
Humans
Hydroxychloroquine
/ adverse effects
Male
Middle Aged
Oxidative Stress
Respiration, Artificial
Respiratory Distress Syndrome
/ blood
Retrospective Studies
SARS-CoV-2
/ isolation & purification
Severity of Illness Index
Sex Distribution
African American
COVID19
G6PD
X-linked
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
07
08
2020
accepted:
03
01
2021
pubmed:
14
1
2021
medline:
5
3
2021
entrez:
13
1
2021
Statut:
ppublish
Résumé
The severe pneumonia caused by the human coronavirus (hCoV)-SARS-CoV-2 has inflicted heavy casualties, especially among the elderly and those with co-morbid illnesses irrespective of their age. The high mortality in African-Americans and males, in general, raises the concern for a possible X-linked mediated process that could affect the viral pathogenesis and the immune system. We hypothesized that G6PD, the most common X-linked enzyme deficiency, associated with redox status, may have a role in severity of pneumonia. Retrospective chart review was performed in hospitalized patients with COVID19 pneumonia needing supplemental oxygen. A total of 17 patients were evaluated: six with G6PD deficiency (G6PDd) and 11 with normal levels. The two groups (normal and G6PDd) were comparable in terms of age, sex, co-morbidities, and laboratory parameters-LDH, IL-6, CRP, and ferritin, respectively. Thirteen patients needed ventilatory support ; 8 in the normal group and 5 in the G6PDd group (72% vs.83%). The main differences indicating increasing severity in normal vs. G6PDd groups included G6PD levels (12.2 vs. 5.6, P = 0.0002), PaO2/FiO2 ratio (159 vs. 108, P = 0.05), days on mechanical ventilation (10.25 vs. 21 days P = 0.04), hemoglobin level (10 vs. 8.1 P = 0.03), and hematocrit (32 vs. 26 P = 0.015). Only one patient with G6PDd died; 16 were discharged home. Our clinical series ascribes a possible biological role for G6PDd in SARS-CoV2 viral proliferation. It is imperative that further studies are performed to understand the interplay between the viral and host factors in G6PDd that may lead to disparity in outcomes. KEY POINTS: • COVID19 studies show higher mortality in men, due to severe pneumonia and ARDS, indicating possible X-linked mediated differences • G6PD, the most common X-linked enzymopathy, highly prevalent in African Americans and Italians, maintains redox homeostasis. • Preclinical studies using G6PD deficient (G6PDd) cells infected with human coronavirus (hCoV), show impaired cellular responses, viral proliferation and worsening oxidative damage. • Retrospective chart review in hospitalized patients with COVID19 pneumonia needing supplemental oxygen shows differences between the two groups (Normal and G6PDd) in hematological indices; the G6PDdgroup demonstrated prolonged PaO2/FiO2 ratio, and longer days on mechanical ventilation indicating the severity of the pneumonia.
Identifiants
pubmed: 33439304
doi: 10.1007/s00277-021-04395-1
pii: 10.1007/s00277-021-04395-1
pmc: PMC7804896
doi:
Substances chimiques
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
667-673Références
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
J Med Virol. 2020 May;92(5):491-494
pubmed: 32056249
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
J Infect Dis. 2008 Mar 15;197(6):812-6
pubmed: 18269318
Viruses. 2018 Jul 26;10(8):
pubmed: 30049972
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Int J Mol Sci. 2016 Dec 09;17(12):
pubmed: 27941691
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
Immunol Res. 2014 Aug;59(1-3):118-28
pubmed: 24845462
Nat Genet. 1997 Nov;17(3):353-6
pubmed: 9354806
N Engl J Med. 1991 Jan 17;324(3):169-74
pubmed: 1984194
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Infect Dis. 2014 Jan;14(1):57-69
pubmed: 24239327
Cell. 2011 Sep 16;146(6):980-91
pubmed: 21925319
Redox Biol. 2020 Jan;28:101363
pubmed: 31707353
J Appl Lab Med. 2018 May 1;2(6):841-850
pubmed: 33636823
Nat Chem Biol. 2008 May;4(5):278-86
pubmed: 18421291
Lancet. 2008 Jan 5;371(9606):64-74
pubmed: 18177777
Viruses. 2015 Dec 17;7(12):6689-706
pubmed: 26694452
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977